IL-33 in COPD: the hunt for responder subgroups
- PMID: 35339232
- DOI: 10.1016/S2213-2600(22)00005-4
IL-33 in COPD: the hunt for responder subgroups
Conflict of interest statement
I report personal fees from Aerogen, AstraZeneca, Boehringer Ingelheim, Chiesi, Cipla, CSL Behring, Epiendo, Genentech, GlaxoSmithKline, Glenmark, Gossamerbio, Kinaset, Menarini, Novartis, Pulmatrix, Sanofi, Synairgen, Teva, Theravance, and Verona. I am supported by the National Institute for Health Research Manchester Biomedical Research Centre.
Comment on
-
Astegolimab, an anti-ST2, in chronic obstructive pulmonary disease (COPD-ST2OP): a phase 2a, placebo-controlled trial.Lancet Respir Med. 2022 May;10(5):469-477. doi: 10.1016/S2213-2600(21)00556-7. Epub 2022 Mar 24. Lancet Respir Med. 2022. PMID: 35339234 Clinical Trial.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical